Overview

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Antiviral Agents
Ritonavir